Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis
Authors:
- Sohei SatoiSSSohei Satoi
- Tsutomu FujiiTFTsutomu Fujii
- Hiroaki YanagimotoHYHiroaki Yanagimoto
- Fuyuhiko MotoiFMFuyuhiko Motoi
- Masanao KurataMKMasanao Kurata
- Naminatsu TakaharaNTNaminatsu Takahara
- Suguru YamadaSYSuguru Yamada
- Tomohisa YamamotoTYTomohisa Yamamoto
- Masamichi MizumaMMMasamichi Mizuma
- Goro HondaGHGoro Honda
- Hiroyuki IsayamaHIHiroyuki Isayama
- Michiaki UnnoMUMichiaki Unno
Open Access
- 1 February 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 265 (2) , 397-401
Abstract
OBJECTIVE To evaluate the clinical efficacy and tolerability of intravenous (i.v.) and intraperitoneal (i.p.) paclitaxel combined with S-1, "an oral fluoropyrimidine derivative containing tegafur, gimestat, and otastat potassium" in chemotherapy-naive pancreatic ductal adenocarcinoma (PDAC) patients with peritoneal metastasis. BACKGROUND PDAC patients with peritoneal metastasis (peritoneal deposits and/or positive peritoneal cytology) have an extremely poor prognosis. An effective treatment strategy remains elusive. METHODS Paclitaxel was administered i.v. at 50 mg/m and i.p. at 20 mg/m on days 1 and 8. S-1 was administered at 80 mg/m/d for 14 consecutive days, followed by 7 days of rest. The primary endpoint was 1-year overall survival (OS) rate. The secondary endpoints were antitumor effect and safety (UMIN000009446). RESULTS Thirty-three patients who were pathologically diagnosed with the presence of peritoneal dissemination (n = 22) and/or positive peritoneal cytology (n = 11) without other organ metastasis were enrolled. The tumor was located at the pancreatic head in 7 patients and the body/tail in 26 patients. The median survival time was 16.3 (11.47-22.57) months, and the 1-year survival rate was 62%. The response rate and disease control rate in assessable patients were 36% and 82%, respectively. OS in 8 patients who underwent conversion surgery was significantly higher than that of nonsurgical patients (n = 25, P = 0.0062). Grade 3/4 hematologic toxicities occurred in 42% of the patients and nonhematologic adverse events in 18%. One patient died of thrombosis in the superior mesenteric artery. CONCLUSIONS This regimen has shown promising clinical efficacy with acceptable tolerability in chemotherapy-naive PDAC patients with peritoneal metastasis.Keywords
This publication has 28 references indexed in Scilit:
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective studyInternational Journal of Clinical Oncology, 2011
- A Randomized Phase II Trial to Test the Efficacy of Intra-peritoneal Paclitaxel for Gastric Cancer with High Risk for the Peritoneal Metastasis (INPACT Trial)Japanese Journal of Clinical Oncology, 2010
- Spatial distribution of intraperitoneally administrated paclitaxel nanoparticles solubilized with poly (2‐methacryloxyethyl phosphorylcholine‐con‐butyl methacrylate) in peritoneal metastatic nodulesCancer Science, 2010
- Weekly Paclitaxel After Failure of Gemcitabine in Pancreatic Cancer Patients with Malignant Ascites: A Retrospective StudyJapanese Journal of Clinical Oncology, 2010
- Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasisAnnals of Oncology, 2009
- Phase I Pharmacokinetic Study of Weekly Intravenous and Intraperitoneal Paclitaxel Combined with S-1 for Advanced Gastric CancerOncology, 2009
- The Influence of Positive Peritoneal Cytology on Survival in Patients With Pancreatic AdenocarcinomaJournal of Gastrointestinal Surgery, 2006
- Intraperitoneal Cisplatin and Paclitaxel in Ovarian CancerNew England Journal of Medicine, 2006
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000